Home >Companies >News >Dr Reddy’s gets FDA nod for anti-cancer drug
Shares of Dr. Reddy’s gained 3.69% to Rs2,305.15 on BSE, while the exchange’s benchmark Sensex rose by 0.31% to 19,804.03 points. Photo: Mint (Mint)
Shares of Dr. Reddy’s gained 3.69% to Rs2,305.15 on BSE, while the exchange’s benchmark Sensex rose by 0.31% to 19,804.03 points. Photo: Mint
(Mint)

Dr Reddy’s gets FDA nod for anti-cancer drug

The launch of product in the market is planned in the near term, says the firm

Hyderabad: Dr Reddy’s Laboratories has secured the approval of the US Food and Drug Administration to launch injectible medicine azacitidine, which is used in the treatment of bone marrow cancer and blood cell disorders, the firm said on Tuesday.

Azacitidine is a copycat version of US-based Celgene Corp.’s Vidaza, which had US sales of approximately $378.5 million in the year ended July, according to IMS Health, a US-based healthcare information provider.

“The launch of product in the market is planned in the near term," Dr Reddy’s said in the statement.

Shares of Dr. Reddy’s gained 3.69% to Rs2,305.15 on BSE, while the exchange’s benchmark Sensex rose by 0.31% to 19,804.03 points.

Subscribe to Mint Newsletters
* Enter a valid email
* Thank you for subscribing to our newsletter.

Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.

Close
×
My Reads Redeem a Gift Card Logout